• 1
    Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853906.
  • 2
    Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 (Suppl. 1): S117S131.
  • 3
    Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217222.
  • 4
    Cosio FG, Alamir A, Yim S et al. Patient survival after renal transplantation. I. The impact of dialysis pre-transplant. Kidney Int 1998; 53: 767772.
  • 5
    Kasiske BL, Ramos EL, Gaston RS. The evaluation of renal transplant candidates. Clinical practice guidelines. J Am Soc Nephrol 1995; 6: 134.
  • 6
    Roodnat JI, Mulder PGH, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 17041710.
  • 7
    Midvedt K, Neumayer HH. Management strategies for posttransplant hypertension. Transplantation 2000; 70: SS64SS69.
  • 8
    Fellström B. Impact and management strategies of hyperlipidemia posttransplantion. Transplantation 2000; 70: SS51SS57.
  • 9
    Jindal RM, Hjelmesaeth J.Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70: SS58SS63.
  • 10
    Jensik SC, and the FK 506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 1998; 30: 12161218.
  • 11
    Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30: 12401242.
  • 12
    Claesson K, Mayer AD, Squifflet JP et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cylosporine A patients. Transplant Proc 1998; 30: 12921294.
  • 13
    Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368373.
  • 14
    Ponticelli C. Calcineurin-inhibitors in renal transplantation. Too precious to be abandoned. Nephrol Dial Transplant 2000; 15: 13071309.
  • 15
    Margreiter R, for the European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741746.
  • 16
    Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Predictors of coronary heart disease using risk factor categories. Circulation 1998; 97: 18371847.
  • 17
    Matthews JNS, Altmann DG, Campbell MJ, Royston P. Analysis of serial measurement in medical research. Br Med J 1990; 300: 230235.
  • 18
    Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 17351743.
  • 19
    Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436443.
  • 20
    Barone G, Bunke CM, Choc MG et al. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. Transplantation 1996; 61: 968970.
  • 21
    Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998; 54: 938944.
  • 22
    Euroaspire I, II. Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 9951001.
  • 23
    Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147152.